Navigation Links
The quest for specific anti-inflammatory treatment
Date:1/8/2009

This release is available in Spanish.

Anti-inflammatory drugs affect the cells taking part in inflammatory processes, but also those that do not. This is why it is important to develop specific anti-inflammatory drugs which affect healthy cells. With this aim in mind, a team from the University of the Basque Country is working on analogues of the C1P molecule.

Today two types of anti-inflammatory pharmaceutical drugs are available: steroids and those known as NSAID (Non-steroidal anti-inflammatory drugs). This second type are the most used, have fewer side-effects but they have an effect over a wider spectrum, i.e. they are less specific. Thus, there are no specific anti-inflammatory drugs for each cell type.

The team led by Antonio Gmez-Muoz, from the Department of Biochemistry and Molecular Biology at the Science and Technology Faculty of the University of the Basque Country (UPV/EHU), is investigating alternatives to current anti-inflammatory drugs, creating synthetic analogues of the C1P (ceramide-1-phosphate) molecule. This molecule was discovered in 1990 in a case of human leukaemia After synthesising it in the laboratory, it was observed that it was an important mytogenic agent (provoking cell growth and blocking the natural death of the cells). Moreover, it causes cell inflammation, i.e. when the cells detect the presence of this molecule, they secrete molecules that generate inflammation - prostaglandin and cytokine cells, for example.

But this process does not occur with all types of cells. Although apparently contradictory, in some cells this same molecule functions in an anti-inflammatory manner. With this in mind, the Basque research team, annulling the inflammatory capacity of the C1P molecule, was able to use it as an anti-inflammatory drug for certain cell types without affecting other cells.

Re
'/>"/>

Contact: Press Office
lucia@elhuyar.com
34-688-673-679
Elhuyar Fundazioa
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Conquest of land began in shark genome
2. UNC study questions FDA genetic-screening guidelines for cancer drug
3. TAU scientists probe deep questions aboard EcoOceans environmental research ship
4. New research on structure of bones raises questions for treatment of osteoporosis
5. Sticky questions tackled in gecko research
6. Computer-based tool aids research, helps thwart questionable publication practices
7. UA-led research team awarded $50 million to solve plant biologys grand challenge questions
8. Cold Spring Harbor Laboratory to play central role addressing key questions in plant biology
9. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
10. A fossilized giant rhino bone questions the isolation of Anatolia, 25 million years ago
11. Answer to troublesome question of why some genetic assoc. studies have failed replication attempts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... who have suffered concussions ready to return to action? ... high school athletes who head back on the field ... regression in their abilities to simultaneously walk and do ... changes in their balance and/or altered walking speed, was ... 12 had returned to activity in less than a ...
(Date:8/20/2014)... spiciness that is irresistible to some, but intolerable to ... their findings to develop a new drug candidate for ... inflammation or other problems. They reported their progress on ... in ACS, Journal of Medicinal Chemistry . , ... had pegged a compound called capsaicin as the active ...
(Date:8/20/2014)... Your chairs, synthetic rugs and plastic bags could one ... waste rather than petroleum, scientists are now reporting. The ... help the world deal with its agricultural and plastic ... . , Athanassia Athanassiou, Ilker S. Bayer and colleagues ... plastic,s popularity is constantly growing. In 2012, its production ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Center for Climate Change (BC3) has analysed the expected economic impact ... the Kyoto Protocol for the period 2008-2012 and for the phase ... come out on top in comparison to sectors such as industrial ... Spain have an impact on the economy, in other words, making ...
... (VBI) at Virginia Tech have constructed a mathematical and ... to simulate the cellular and molecular changes underlying chronic ... to explore different interactions of cells in the immune ... in the colon, and identify intervention points to perhaps ...
... HOUSTON -- A novel approach detects genetically abnormal cells in ... abnormalities found in tumor cells and increase in number with ... scientists at The University of Texas MD Anderson Cancer Center ... Lung cancer patients in the study also had many times ...
Cached Biology News:CO2 reduction policies in Spain strengthen the services sector 2Math model of colon inflammation singles out dangerous immune cells 2Math model of colon inflammation singles out dangerous immune cells 3UT MD Anderson study ties abnormal cells in blood to lung cancer 2UT MD Anderson study ties abnormal cells in blood to lung cancer 3
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... Oxide Fuel Cells (SOFCs) - Global Strategic Business Report" ... the worldwide markets for Solid Oxide Fuel Cells (SOFCs) in ... US, Canada , Europe ... Annual estimates and forecasts are provided for the period 2012 ...
(Date:8/19/2014)... , Aug. 19, 2014 ... the addition of the "Spectroscopy Equipment ... report to their offering. ... for Spectroscopy Equipment and Accessories in US$ ... Spectroscopy (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, ...
(Date:8/19/2014)... Aug. 19, 2014   Synthetic Biologics, Inc. ... novel anti-infective biologic and drug programs targeting specific ... today that its novel C. difficile ... th Interscience Conference on Antimicrobial Agents and ... D.C. Synthetic Biologics, Senior ...
(Date:8/18/2014)... 19, 2014 2014 Deep Research ... a professional and in-depth research report on the ... information, including its definition, classification, application, and ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis. ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it ... a lawsuit in U.S. District Court in Delaware ... Laboratories,Inc., for infringement of U.S. Patent Nos. 6,200,604 ... Cephalon product FENTORA(R) (fentanyl buccal,tablet) [C-II]. The 6,200,604 ...
... iCAD, Inc. (Nasdaq:,ICAD), an industry-leading provider of Computer-Aided ... Executive Officer, and,Darlene Deptula-Hicks, Executive Vice President and ... corporate update at the Seventh Annual,Needham and Company ... 2008 at 2:00 p.m., (Eastern Daylight Time) at ...
... changes and further organizational ... consolidation ... Paul LaViolette to retire ... that President and Chief Executive,Officer Jim Tobin will be extending his tenure at the Company. The ...
Cached Biology Technology:Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals 3iCAD to Present at Seventh Annual Needham and Company Biotechnology and Medical Technology Conference 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 3Boston Scientific Announces CEO Jim Tobin to Extend Tenure 4Boston Scientific Announces CEO Jim Tobin to Extend Tenure 5
... offers single pass sequencing of plasmids ... fueled by our high performance sequencing ... Phred20 bases per day. The key ... sequencing customers are rapid turnaround, high ...
... Agencourt offers quick turnaround sequencing of ... copy and high copy plasmids. Agencourt's world-class, ... million Phred20 bases per day. The ... Sequencing service are 24 48 hour ...
Sequencing and primer design rolled into one. Just give us your clone and a reference sequence, and we'll do the rest. Single-strand or double-strand coverage. Guaranteed results....
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
Biology Products: